scholarly journals Overview of Congenital Hepatic Fibrosis in Pediatrics: A Review

Author(s):  
Ahmed Abdelsamie Fadl ◽  
Sarah jamal Almujil ◽  
Ahmed Saeed S. Banheem ◽  
Nasser Naif Alsuhaymi ◽  
Mansour Hemaid Alhelali ◽  
...  

Congenital hepatic fibrosis is a rare developmental illness caused by a ductal plate malformation, often known as ciliopathy or fibrocystic liver disease. Hepatosplenomegaly and portal hypertension are two symptoms. The disease affects 1/10000–20000 people. frequently associated with a variety of illnesses caused by genetic abnormalities, such as autosomal recessive polycystic kidney disease (ARPKD) and Caroli syndrome. There hasn't been a way to stop or reverse the progression of congenital hepatic fibrosis until now. Clinical trials of anti-fibrotic medicines such as colchicine, interferon gamma, angiotensin II receptor blockers, pirfenidone, and ursodeoxycholic acid found no significant benefit. The only known cure for CHF is liver transplantation, which is recommended when the condition has progressed to the point when symptoms of liver failure have appeared. In this article we will be making overview of the disease. It’s symptoms and diagnosis, different treatment method, and we will compare some of the articles published about the disease.

2008 ◽  
Vol 39 (2) ◽  
pp. 100-111 ◽  
Author(s):  
Baris Turkbey ◽  
Iclal Ocak ◽  
Kailash Daryanani ◽  
Esperanza Font-Montgomery ◽  
Linda Lukose ◽  
...  

2016 ◽  
Vol 2016 ◽  
pp. 1-10 ◽  
Author(s):  
Lu Jiang ◽  
Pingping Fang ◽  
James L. Weemhoff ◽  
Udayan Apte ◽  
Michele T. Pritchard

Autosomal recessive polycystic kidney disease (ARPKD) is a severe monogenic disorder that occurs due to mutations in thePKHD1gene. Congenital hepatic fibrosis (CHF) associated with ARPKD is characterized by the presence of hepatic cysts derived from dilated bile ducts and a robust, pericystic fibrosis. Cyst growth, due to cyst wall epithelial cell hyperproliferation and fluid secretion, is thought to be the driving force behind disease progression. Liver fibrosis is a wound healing response in which collagen accumulates in the liver due to an imbalance between extracellular matrix synthesis and degradation. Whereas both hyperproliferation and pericystic fibrosis are hallmarks of CHF/ARPKD, whether or not these two processes influence one another remains unclear. Additionally, recent studies demonstrate that inflammation is a common feature of CHF/ARPKD. Therefore, we propose a “pathogenic triumvirate” consisting of hyperproliferation of cyst wall growth, pericystic fibrosis, and inflammation which drives CHF/ARPKD progression. This review will summarize what is known regarding the mechanisms of cyst growth, fibrosis, and inflammation in CHF/ARPKD. Further, we will discuss the potential advantage of identifying a core pathogenic feature in CHF/ARPKD to aid in the development of novel therapeutic approaches. If a core pathogenic feature does not exist, then developing multimodality therapeutic approaches to target each member of the “pathogenic triumvirate” individually may be a better strategy to manage this debilitating disease.


2020 ◽  
Vol 131 (1-2) ◽  
pp. 267-276
Author(s):  
Nehna Abdul Majeed ◽  
Esperanza Font-Montgomery ◽  
Linda Lukose ◽  
Joy Bryant ◽  
Peter Veppumthara ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document